<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Eur Urol</journal-id>
        <journal-id journal-id-type="iso-abbrev">Eur Urol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>European urology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0302-2838</issn>
        <issn pub-type="epub">1873-7560</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7572747</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7572747.1</article-id>
        <article-id pub-id-type="pmcaid">7572747</article-id>
        <article-id pub-id-type="pmcaiid">7572747</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1605995</article-id>
        <article-id pub-id-type="pmid">32317181</article-id>
        <article-id pub-id-type="doi">10.1016/j.eururo.2020.03.024</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1605995</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1605995</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Pan-cancer Analysis of <italic toggle="yes">CDK12</italic> Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nguyen</surname>
              <given-names initials="B">Bastien</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A2">b</xref>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mota</surname>
              <given-names initials="JM">Jose Mauricio</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nandakumar</surname>
              <given-names initials="S">Subhiksha</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A2">b</xref>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Stopsack</surname>
              <given-names initials="KH">Konrad H.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Weg</surname>
              <given-names initials="E">Emily</given-names>
            </name>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rathkopf</surname>
              <given-names initials="D">Dana</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Morris</surname>
              <given-names initials="MJ">Michael J.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Scher</surname>
              <given-names initials="HI">Howard I.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kantoff</surname>
              <given-names initials="PW">Philip W.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gopalan</surname>
              <given-names initials="A">Anuradha</given-names>
            </name>
            <xref ref-type="aff" rid="A7">g</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zamarin</surname>
              <given-names initials="D">Dmitriy</given-names>
            </name>
            <xref ref-type="aff" rid="A8">h</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A2">b</xref>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A2">b</xref>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Abida</surname>
              <given-names initials="W">Wassim</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
            <xref rid="CR1" ref-type="corresp">*</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>a</label>Marie-Jos√©e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A2"><label>b</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A3"><label>c</label>Department of Epidemiology &amp; Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A4"><label>d</label>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A5"><label>e</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A6"><label>f</label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A7"><label>g</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A8"><label>h</label>Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <author-notes>
          <fn fn-type="con" id="FN1">
            <p id="P1"><bold><italic toggle="yes">Author contributions:</italic></bold> Wassim Abida had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
            <p id="P2"><italic toggle="yes">Study concept and design:</italic> Nguyen, Mota, Nandakumar, Gopalan, Schultz, Abida.</p>
            <p id="P3"><italic toggle="yes">Acquisition of data:</italic> Nguyen, Mota, Nandakumar, Stopsack, Weg, Rathkopf, Morris, Scher, Zamarin, Abida.</p>
            <p id="P4"><italic toggle="yes">Analysis and interpretation of data:</italic> Nguyen, Mota, Nandakumar, Stopsack, Kantoff, Gopalan, Zamarin, Solit, Schultz, Abida.</p>
            <p id="P5"><italic toggle="yes">Drafting of the manuscript:</italic> Nguyen, Mota, Stopsack, Schultz, Abida. Critical revision of the manuscript for important intellectual content: All authors.</p>
            <p id="P6"><italic toggle="yes">Statistical analysis:</italic> Nguyen, Stopsack, Schultz.</p>
            <p id="P7"><italic toggle="yes">Obtaining funding:</italic> Scher, Solit, Abida.</p>
            <p id="P8">Administrative, technical, or material support: Morris, Scher, Kantoff, Schultz, Abida.</p>
            <p id="P9"><italic toggle="yes">Supervision:</italic> Schultz, Abida.</p>
            <p id="P10"><italic toggle="yes">Other:</italic> None.</p>
          </fn>
          <fn fn-type="con" id="FN2">
            <p id="P11">CRediT authorship contribution statement</p>
            <p id="P12"><bold>Bastien Nguyen:</bold> Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft, Writing - review &amp; editing. <bold>Jose Mauricio Mota:</bold> Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review &amp; editing. <bold>Subhiksha Nandakumar:</bold> Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - review &amp; editing. <bold>Konrad H. Stopsack:</bold> Methodology, Validation, Writing - review &amp; editing. <bold>Emily Weg:</bold> Writing - review &amp; editing. <bold>Dana Rathkopf:</bold> Writing - review &amp; editing. <bold>Michael J. Morris:</bold> Writing - review &amp; editing. <bold>Howard I. Scher:</bold> Funding acquisition, Writing - review &amp; editing. <bold>Philip W. Kantoff:</bold> Funding acquisition, Writing - review &amp; editing. <bold>Anuradha Gopalan:</bold> Formal analysis, Investigation, Writing - review &amp; editing. <bold>Dmitriy Zamarin:</bold> Investigation, Validation, Writing - review &amp; editing. <bold>David B. Solit:</bold> Supervision, Writing - review &amp; editing. <bold>Nikolaus Schultz:</bold> Conceptualization, Funding acquisition, Supervision, Writing - original draft, Writing - review &amp; editing. <bold>Wassim Abida:</bold> Conceptualization, Funding acquisition, Supervision, Writing - original draft, Writing - review &amp; editing.</p>
          </fn>
          <corresp id="CR1"><label>*</label>Corresponding author. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Tel. +1 646 4224633. <email>abidam@mskcc.org</email> (W. Abida).</corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>19</day>
          <month>4</month>
          <year>2020</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>11</month>
          <year>2020</year>
        </pub-date>
        <volume>78</volume>
        <issue>5</issue>
        <issue-id pub-id-type="pmc-issue-id">367196</issue-id>
        <fpage>671</fpage>
        <lpage>679</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>09</day>
              <month>07</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>11</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>11</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-16 19:25:15.590">
              <day>16</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1605995.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Background</title>
            <p id="P13"><italic toggle="yes">CDK12</italic> genomic alterations occur in several tumor types, but little is known about their oncogenic role and clinical significance.</p>
          </sec>
          <sec id="S2">
            <title>Objective</title>
            <p id="P14">To describe the landscape of <italic toggle="yes">CDK12</italic> alterations across solid cancers and the clinical features of <italic toggle="yes">CDK12</italic>-altered prostate cancer.</p>
          </sec>
          <sec id="S3">
            <title>Design, setting, and participants</title>
            <p id="P15">A single-center retrospective study of 26743 patients across 25 solid tumor types who underwent tumor sequencing was performed. Clinicopathologic features and outcomes were assessed in prostate cancer.</p>
          </sec>
          <sec id="S4">
            <title>Outcome measurements and statistical analysis</title>
            <p id="P16"><italic toggle="yes">CDK12</italic> alterations and their association with genomic characteristics are described. For prostate cancer patients, overall survival and time to castration resistance were assessed using univariable and multivariable Cox regression analysis.</p>
          </sec>
          <sec id="S5">
            <title>Results and limitations</title>
            <p id="P17"><italic toggle="yes">CDK12</italic> alterations were identified in 404/26743 patients (1.5%) overall, but were most frequent in prostate (100/1875, 5.3%) and ovarian cancer (43/1034, 4.2%), in which they were associated with a high prevalence of truncating variants and biallelic inactivation. <italic toggle="yes">CDK12</italic> alterations defined a genomic subtype of prostate cancer with a unique copy-number alteration profile and involvement of distinct oncogenic pathway alterations, including cell-cycle pathway genes. <italic toggle="yes">CDK12</italic>-altered prostate cancer was associated with somewhat more aggressive clinical features and shorter overall survival (median 64.4 vs 74.9 mo; <italic toggle="yes">p</italic> = 0.032) independent of standard clinical factors and tumor copy-number alteration burden (adjusted hazard ratio 1.80, 95% confidence interval 1.12‚Äì2.89; <italic toggle="yes">p</italic> = 0.024). The study is limited by its retrospective nature.</p>
          </sec>
          <sec id="S6">
            <title>Conclusions</title>
            <p id="P18"><italic toggle="yes">CDK12</italic> alteration is a rare event across solid cancers but defines a clinically distinct molecular subtype of prostate cancer associated with unique genomic alterations and slightly more aggressive clinical features.</p>
          </sec>
          <sec id="S7">
            <title>Patient summary</title>
            <p id="P19"><italic toggle="yes">CDK12</italic> gene alterations occur rarely across tumor types, but more frequently in prostate cancer, where they are associated with genomic instability, cell-cycle pathway gene alterations, and somewhat worse clinical outcomes, warranting further investigation of therapeutic targeting of this disease subset.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>
            <italic toggle="yes">CDK12</italic>
          </kwd>
          <kwd>Clinical sequencing</kwd>
          <kwd>Genomics</kwd>
          <kwd>Prostate cancer</kwd>
          <kwd>Tumor biology</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
